LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Foretinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3955 | 3772 | 1.0486 | 1.0715 |
| BT-20 | Saracatinib | 0.04 | uM | LJP6 | 72 | hr | 1657 | 5648 | 5383 | 1.0488 | 1.0562 |
| SK-BR-3 | Saracatinib | 0.37 | uM | LJP6 | 72 | hr | 1476 | 3815 | 3643 | 1.0498 | 1.0808 |
| MDA-MB-231 | PHA-665752 | 1.11 | uM | LJP5 | 72 | hr | 868 | 3577 | 3410 | 1.0503 | 1.0495 |
| Hs 578T | KIN001-043 | 0.37 | uM | LJP6 | 72 | hr | 929 | 3379 | 3216 | 1.0505 | 1.0556 |
| MCF 10A | Nilotinib | 1.11 | uM | LJP5 | 72 | hr | 513 | 10885 | 10362 | 1.0506 | 1.0228 |
| MDA-MB-231 | Celastrol | 0.12 | uM | LJP6 | 72 | hr | 868 | 3735 | 3556 | 1.0507 | 1.0492 |
| Hs 578T | CP466722 | 1.11 | uM | LJP5 | 72 | hr | 929 | 3402 | 3237 | 1.0509 | 1.0560 |
| SK-BR-3 | NVP-AEW541 | 1.11 | uM | LJP5 | 72 | hr | 1476 | 3963 | 3772 | 1.0510 | 1.0749 |
| SK-BR-3 | NU7441 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3965 | 3772 | 1.0513 | 1.0755 |
| MDA-MB-231 | PD184352 | 0.04 | uM | LJP5 | 72 | hr | 868 | 3587 | 3410 | 1.0514 | 1.0513 |
| MCF 10A | TWS119 | 0.04 | uM | LJP5 | 72 | hr | 513 | 10892 | 10362 | 1.0515 | 1.0230 |
| MCF 10A | TWS119 | 0.37 | uM | LJP5 | 72 | hr | 513 | 10898 | 10362 | 1.0517 | 1.0233 |
| SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3824 | 3643 | 1.0518 | 1.0833 |
| MDA-MB-231 | NVP-AEW541 | 0.37 | uM | LJP5 | 72 | hr | 868 | 3583 | 3410 | 1.0521 | 1.0514 |
| MDA-MB-231 | PHA-665752 | 0.04 | uM | LJP5 | 72 | hr | 868 | 3586 | 3410 | 1.0523 | 1.0523 |
| SK-BR-3 | R406 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 3826 | 3643 | 1.0525 | 1.0844 |
| MCF7 | PHA-665752 | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4485 | 4267 | 1.0528 | 1.0586 |
| MCF 10A | Imatinib | 10 | uM | LJP6 | 72 | hr | 513 | 11029 | 10473 | 1.0531 | 1.0238 |
| SK-BR-3 | AZD-6482 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3972 | 3772 | 1.0531 | 1.0773 |
| SK-BR-3 | Imatinib | 0.12 | uM | LJP6 | 72 | hr | 1476 | 3841 | 3643 | 1.0535 | 1.0802 |
| SK-BR-3 | Vemurafenib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 3973 | 3772 | 1.0535 | 1.0786 |
| BT-20 | PIK-93 | 0.37 | uM | LJP5 | 72 | hr | 1657 | 5886 | 5588 | 1.0536 | 1.0605 |
| MDA-MB-231 | PIK-93 | 0.04 | uM | LJP5 | 72 | hr | 868 | 3598 | 3410 | 1.0547 | 1.0539 |
| MCF 10A | Nilotinib | 0.04 | uM | LJP5 | 72 | hr | 513 | 10927 | 10362 | 1.0548 | 1.0246 |